1[1]Rosenfeld WE,Sachdeo RC,Faught RE,et al.Long-term experience with TPM as adjunctive therapy and as monotherapy in patients with partial onset seizures:retrospective survey of open-label treatment. Epilepsia,1997,38:34～36.
2[2]Ramsay RE, Sater JD. Antiepileptic drugs in clinical development.New antiepileptic drug development:preclinical and clinical aspects. New York:Elsevier Science Publishers.1993:45～67.
3[3]Elferink AJ, Van ZwietenB BJ. Analysis based on number needed to treat shows differences between drugs studied.BJM,1997,314:603～604.
4[4]Shank RP,Gardocki JF,Vaught JL,et al.Topiramate:preclinical evaluation of a structurally novel anticonvulsant.Epilepsia,1994,35:450～460.
5[5]Gisclon LG,Curtin CR,Kramer LD.The steady-state (SS) pharmacokinetics (PK) of phenytoin and topiramate in epileptic patients on monotherapy and during combination therapy.Epilepsia,1994,35:54～56.
7[8]Reife R,Pledger G,Wu SC.Topiramate as add-on therapy:poolded analysis of randomized controlled trials in adults. Epilepsia,2000,41:66～69.
8[9]Chadwick DW.An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia,1997,38:59～62.
9[10]Privitera M,Fincham R,Penry J,et al.Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-,800-,and 1000-mg daily dosages.Neurology,1996,46:168～190.
10[11]Ritter F,Glauser TA,Elterman RD,et al.Effectiveness,tolerability,and safety of topiramate in children with partial-onset seizures.Epilepsia,2000,41:82～85.
